Universität zu Köln

Navaratnam, Kate, Alfirevic, Zarko, Baker, Philip N., Gluud, Christian ORCID: 0000-0002-8861-0799, Gruettner, Berthold, Kublickiene, Karolina ORCID: 0000-0002-4841-6836, Zeeman, Gerda and Kenny, Louise C. (2013). A multi-centre phase IIa clinical study of predictive testing for preeclampsia: improved pregnancy outcomes via early detection (IMPROvED). BMC Pregnancy Childbirth, 13. LONDON: BIOMED CENTRAL LTD. ISSN 1471-2393

Full text not available from this repository.

Abstract

Background: 5% of first time pregnancies are complicated by pre-eclampsia, the leading cause of maternal death in Europe. No clinically useful screening test exists; consequentially clinicians are unable to offer targeted surveillance or preventative strategies. IMPROvED Consortium members have pioneered a personalised medicine approach to identifying blood-borne biomarkers through recent technological advancements, involving mapping of the blood metabolome and proteome. The key objective is to develop a sensitive, specific, high-throughput and economically viable early pregnancy screening test for pre-eclampsia. Methods/Design: We report the design of a multicentre, phase IIa clinical study aiming to recruit 5000 low risk primiparous women to assess and refine innovative prototype tests based on emerging metabolomic and proteomic technologies. Participation involves maternal phlebotomy at 15 and 20 weeks' gestation, with optional testing and biobanking at 11 and 34 weeks. Blood samples will be analysed using two innovative, proprietary prototype platforms; one metabolomic based and one proteomic based, both of which outperform current biomarker based screening tests at comparable gestations. Analytical and clinical data will be collated and analysed via the Copenhagen Trials Unit. Discussion: The IMPROvED study is expected to refine proteomic and metabolomic panels, combined with clinical parameters, and evaluate clinical applicability as an early pregnancy predictive test for pre-eclampsia. If 'at risk' patients can be identified, this will allow stratified care with personalised fetal and maternal surveillance, early diagnosis, timely intervention, and significant health economic savings. The IMPROvED biobank will be accessible to the European scientific community for high quality research into the cause and prevention of adverse pregnancy outcome. Trial registration: Trial registration number NCT01891240 The IMPROvED project is funded by the seventh framework programme for Research and Technological development of the EU. http://www.fp7-improved.eu/

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Navaratnam, Kate UNSPECIFIED UNSPECIFIED UNSPECIFIED Alfirevic, Zarko UNSPECIFIED UNSPECIFIED UNSPECIFIED Baker, Philip N. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gluud, Christian UNSPECIFIED orcid.org/0000-0002-8861-0799 UNSPECIFIED Gruettner, Berthold UNSPECIFIED UNSPECIFIED UNSPECIFIED Kublickiene, Karolina UNSPECIFIED orcid.org/0000-0002-4841-6836 UNSPECIFIED Zeeman, Gerda UNSPECIFIED UNSPECIFIED UNSPECIFIED Kenny, Louise C. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-470234
DOI:	10.1186/1471-2393-13-226
Journal or Publication Title:	BMC Pregnancy Childbirth
Volume:	13
Date:	2013
Publisher:	BIOMED CENTRAL LTD
Place of Publication:	LONDON
ISSN:	1471-2393
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language DISEASE; PREVENTION; BIOMARKERS Multiple languages Obstetrics & Gynecology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/47023